Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Consolidated Net Income: 2010-2025

Historic Consolidated Net Income for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Consolidated Net Income rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $163.4 million for FY2024, which is 174.43% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Consolidated Net Income stood at $52.8 million for Q3 2025, which was up 1.30% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Consolidated Net Income registered a high of $56.7 million during Q1 2025, and its lowest value of -$30.8 million during Q3 2023.
  • Its 3-year average for Consolidated Net Income is $35.0 million, with a median of $40.8 million in 2024.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 235.24% in 2023, then soared by 242.65% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Consolidated Net Income (Quarterly) stood at $9.3 million in 2021, then surged by 173.62% to $25.5 million in 2022, then decreased by 9.82% to $23.0 million in 2023, then skyrocketed by 141.33% to $55.4 million in 2024, then increased by 20.28% to $52.8 million in 2025.
  • Its last three reported values are $52.8 million in Q3 2025, $52.1 million for Q2 2025, and $56.7 million during Q1 2025.